From Bristol Myers Squibb expanding their cardiovascular partnership with Avidity Biosciences' antibody-oligonucleotide conjugate technology, to Nurix and Seagen collaborating on a targeted protein degradation conjugate, there is now a staggering amount of investment and collaboration in the novel […]